WHENOctober 14, 2016 @ 8:00am - 5:00pm

DATE: Thursday, October 27, 2016
TIME: 6:00 – 6:30 PM Registration, Networking and Light dinner
6:30 – 7:15 PM Dr. Pierre-Yves Michellys, “Discovery of Zykadia”
7:15 – 8:00 PM Professor David W. C. MacMillan, topic TBD
PLACE: Knobbe Martens Olson & Bear LLP 12790 El Camino Real, San Diego, CA 92130

FREE REGISTRATION: https://www.eventbrite.com/e/6th-sabpaacs-chemistry-symposium-tickets-28516312057


David W. C. MacMillan
David W. C. MacMillan
PhD, James S. McDonnell Distinguished University Professor of Chemistry, Princeton University

Dave MacMillan was born in Bellshill, Scotland and received his undergraduate degree in chemistry at the University of Glasgow, where he worked with Dr. Ernie Colvin. In 1990, he began his doctoral studies under the direction of Professor Larry Overman at the University of California, Irvine, before undertaking a postdoctoral position with Professor Dave Evans at Harvard University (1996). He began his independent career at University of California, Berkeley in July of 1998 before moving to Caltech in June of 2000 (Earle C. Anthony Chair of Organic Chemistry). In 2006, Dave moved to the east coast of the US to take up the position of James S. McDonnell Distinguished University Professor at Princeton University and he served as Department Chair from 2010-15. Dave has received several awards including the Janssen Pharmaceutica Prize (2016), Max Tischler Prize Harvard (2016), Ernst Schering Award in Biology, Chemistry and Medicine, Germany (2015), ACS Harrison Howe Award (2014), NJ ACS Molecular Design Award (2014), ACS Award for Creativity in Synthesis (2011), the Mitsui Catalysis Award (2011), ACS Cope Scholar Award (2007), ACS EJ Corey Award (2005), the Corday-Morgan Medal (2005). In 2012 Dave became a Fellow of the Royal Society (FRS) and a Fellow of the American Academy of Arts and Sciences. Dave helped launch and was editor-in-chief of Chemical Sciences (2009-1014) and is currently Chair of the NIH Study Section SBCA. Dave is a scientific consultant with Merck (worldwide), Amgen (worldwide), Biogen Biopharma, Abbvie Research Laboratories, Johnson & Johnson Pharmaceuticals, UCB-Celtech, Constellation Pharmaceuticals and Gilead Research Laboratories.  Dave is also a member of the scientific advisory boards of Firmenich (Switzerland) and Kadmon Pharmaceuticals (US), and a permanent member of the RSRC board at Merck Research Laboratories. Along with Dr. Paul Reider, Dave is a co-founder of Chiromics LLC, a growing biotech that seeks to devise new strategies and screening techniques for the identification of drug-like molecules. 

Pierre-Yves Michellys
Pierre-Yves Michellys
PhD, Director of Medicinal chemistry, Genomics Institute of the Novartis Research Foundation

Pierre-Yves Michellys received his Ph.D in 1995 at the University of Science and Techniques of Saint Jerome in Marseille (France). In October 1995 he joined the laboratory of Professor Barry M. Trost in Stanford University for his post-doctoral studies where he contributed to the optimization of a methodology of macrocycle synthesis using a novel cycloisomerization of allene. He began his career as a medicinal chemist at Ligand Pharmaceuticals in 1997; where he was involved in research associated with nuclear hormone receptors. In 2003, he joined the Genomics Institute of the Novartis Research Foundation (GNF) where he is currently a Director of medicinal chemistry. Pierre-Yves Michellys was the medicinal chemistry team leader of the anaplastic lymphoma kinase (ALK) inhibitor project at GNF that enabled the discovery of LDK378 (ceritinib), which became the first ALK inhibitor approved by the FDA (zykadiaTM) to treat crizotinib-resistant patients. Under his supervision, his group has also provided three additional small-molecule candidates that have entered PhI clinical evaluation for oncology and metabolic diseases. He is currently involved in the discovery of novel innovative medicines for unmet medical needs in several disease areas.